Three numbers tell the whole Journey Medical story right now: $6.3 million, $2.1 million, and 85%. Emrosi revenue tripled year-over-year in Q1 2026, payer coverage now reaches roughly 85% of commercial lives nationally, and the company flipped to positive adjusted EBITDA — $0.6 million — after burning nearly $1 million on the same metric a year ago. For a single-asset growth story in a crowded specialty dermatology market, that trajectory is not incremental. It is structural.
The strategic logic sharpens when you look at what drove the coverage expansion. Securing a contract with the third-largest GPO in the country — announced April 21 — is not a routine formulary win. GPO contracts in dermatology compress the access gap between well-resourced academic health systems and smaller practices, exactly the prescriber universe a company with eight salespeople and a lean commercial model needs to penetrate. Journey Medical is not outspending Galderma or Sun Pharma on promotion. It is engineering coverage density to do the conversion work that a larger field force would otherwise handle. The 29,968 prescriptions in Q1, up from 27,023 in Q4 2025, confirm the approach is generating sequential volume — not just launch-period noise.
The gross margin dip to 61% from 63.5% deserves honest context. The entire deterioration traces to a one-time $1.3 million non-cash API write-down tied to the 2021 Qbrexza asset acquisition — an artifact of legacy inventory accounting, not a sign of pricing pressure or supply-chain dysfunction. Underlying unit economics on Emrosi are intact, and SG&A actually contracted by $500,000 year-over-year as launch spending normalized. That combination — rising revenue, stable cost base, shrinking net loss from $4.1 million to $2.2 million — describes a business achieving operating leverage without raising capital. Cash grew to $27.2 million from $24.1 million in a single quarter. Journey Medical is self-funding its own inflection.
The one number that will determine whether this momentum compounds or plateaus is refill rate. Prescription volume growth is encouraging, but a rosacea treatment succeeds commercially only if patients stay on it past the first fill. If refill rates are rising — and the company’s own framing suggests they are — Emrosi’s revenue line becomes increasingly durable and less dependent on continuously acquiring new prescribers. Watch the Q2 prescription-to-revenue ratio for confirmation that repeat demand, not just new trial, is driving the curve.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
